Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis

Background The effectiveness and cost‐effectiveness of using neoadjuvant FOLFIRINOX (nFOLFIRINOX) for patients with borderline resectable or locally advanced pancreatic ductal adenocarcinoma (BR/LA PDAC) are unknown. Our objective was to determine whether nFOLFIRINOX is more effective or cost‐effect...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	The oncologist (Dayton, Ohio) Ohio), 2019-07, Vol.24 (7), p.945-954
Hauptverfasser:	Choi, Jin G., Nipp, Ryan D., Tramontano, Angela, Ali, Ayman, Zhan, Tiannan, Pandharipande, Pari, Dowling, Emily C., Ferrone, Cristina R., Hong, Theodore S., Schrag, Deborah, Fernandez‐Del Castillo, Carlos, Ryan, David P., Kong, Chung Yin, Hur, Chin
Format:	Artikel
Sprache:	eng
Schlagworte:	Computer simulation Cost‐benefit analysis Decision support techniques Health Outcomes and Economics of Cancer Care Pancreatic neoplasms
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!